SteinCares and Shilpa Biologicals Strike into Licensing Agreement to Expand Access to Biosimilars Across Latin America
Feb 25, 2026
San Jose [Costa Rica]/ Raichur (Karnataka) [India], February 25: SteinCares, a leading specialty healthcare company in Latin America, and Shilpa Biologicals Pvt. Ltd. (SBPL), a fully integrated biopharmaceutical subsidiary of Shilpa Medicare Limited (BSE: 530549) (NSE: SHILPAMED), announce a strategic licensing agreement to commercialize a biosimilar across Latin America. New partnership combines Shilpa Biologicals' development and manufacturing capabilities with SteinCares' regional commercialization platform. Collaboration aims to expand patient access to cost-effective treatments and reinforces SteinCares' leadership in biosimilars across Latin America. Agreement marks the first product from this strategic partnership and Shilpa Biologicals' entry into the Latin American market.
Read More...
